Guangdong Provincial People's Hospital (GDPH): National Benchmark in Precision Lung Cancer Care & Comprehensive Oncology

Founded in 1946, Guangdong Provincial People's Hospital (GDPH / 广东省人民医院) is one of China's premier Class A Tertiary comprehensive medical institutions and a designated National Regional Medical Center. Centrally located on Zhongshan 2nd Road in the medical district of Yuexiu, Guangzhou, GDPH combines world-class clinical care, pioneering clinical research, and extensive medical education across over 50 specialized departments.

Key Clinical Specialties & Breakthrough Strengths

1. 🫁 National Pioneer in Lung Cancer Precision Oncology (Prof. Wu Yilong's Team)

The Guangdong Lung Cancer Institute at GDPH is widely recognized as one of the most authoritative centers globally for personalized lung cancer treatment:

• First-Line Molecular-Guided Therapy: Routine comprehensive Next-Generation Sequencing (NGS) panels detecting rare and common oncogenic mutations (EGFR, ALK, ROS1, KRAS G12C, MET exon 14 skipping, RET, BRAF, HER2).
• Overcoming Targeted Drug Resistance: Unrivaled clinical acumen in managing acquired resistance to third-generation EGFR-TKIs and ALK inhibitors, formulating customized combination therapies (e.g., dual-targeted, ADC-targeted, or bypass-pathway interventions).
• Immuno-Oncology Leadership: Leading clinical investigations into perioperative neoadjuvant and adjuvant immunotherapy regimens that significantly improve pathological complete response (pCR) rates and survival in resectable and locally advanced non-small cell lung cancer (NSCLC).

2. 🔍 Early Pulmonary Nodule Precision Management

Dedicated early-stage lung nodule diagnostics and organ-preserving surgery:

• Advanced multi-detector high-resolution CT (LDCT) protocols with AI-enhanced reconstruction for evaluating suspicious ground-glass opacities (GGOs) and sub-centimeter pulmonary nodules.
• Minimally invasive uniportal Video-Assisted Thoracoscopic Surgery (VATS) and robotic-assisted anatomical segmentectomies that achieve complete oncologic resection while preserving maximum healthy lung parenchyma.

3. 💊 Premier Hub for Innovative Cancer Clinical Trials (GCP)

GDPH operates one of the most prolific and active clinical trial centers in Asia, offering patients with advanced, refractory, or rare cancers early access to:

• Novel Antibody-Drug Conjugates (ADCs) targeting TROP2, HER2, HER3, B7-H3, and Claudin 18.2;
• Next-generation bispecific and multi-specific antibodies (e.g., PD-1/CTLA-4, PD-1/VEGF);
• Fourth-generation targeted small molecules designed specifically for resistance mutations;
• Investigational cell therapies and cancer vaccine clinical protocols.

4. 🎀 Breast Oncology Center

Providing multidisciplinary, personalized care for breast malignancies:

• High-precision oncoplastic breast-conserving surgery, sentinel lymph node mapping, and immediate aesthetic breast reconstruction.
• Subtype-tailored neoadjuvant regimens for HER2-positive and triple-negative breast cancer (TNBC).
• Genetic counseling, BRCA risk assessment, and molecular-targeted maintenance strategies.

5. 🔬 Gastrointestinal Oncology Center

Integrating advanced minimally invasive surgical techniques with perioperative systemic therapies:

• 3D laparoscopic and robotic radical surgeries for gastric, colorectal, and gastroesophageal junction carcinomas.
• Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and multimodal interventions for selected advanced or peritoneal cases.
• Biomarker-directed immunotherapy protocols for microsatellite instability-high (MSI-H/dMMR) tumors.

Distinguished Multidisciplinary Team (MDT) System

GDPH's oncology care model is anchored in rigorous Multidisciplinary Tumor Boards (MDT). Each complex patient case is reviewed collaboratively by experts across:

• Thoracic surgeons and surgical oncologists
• Pulmonary physicians and medical oncologists
• Radiation therapists and medical physicists
• Subspecialty pathologists and molecular geneticists
• Diagnostic and interventional radiologists

This coordinated panel approach eliminates diagnostic ambiguity and ensures every patient embarks on a scientifically validated therapeutic plan.

Hospital Location & Facilities

• Main Hospital Address: 106 Zhongshan 2nd Road, Yuexiu District, Guangzhou, Guangdong, China (广州市越秀区中山二路106号)
• Facility Tier: Class A Tertiary Comprehensive General Hospital (国家三级甲等综合性医院)
• Core Academic Platform: Guangdong Lung Cancer Institute (GLCI / 广东省肺癌研究所)

Medical Records Recommended for Specialist Review

International and out-of-province patients seeking consultation or clinical trial evaluation are encouraged to prepare:

• Pathology & Biopsy Reports: Histopathology, cytology, and detailed immunohistochemical (IHC) diagnostic profiles;
• Molecular Diagnostics: Comprehensive NGS genomic reports, circulating tumor DNA (ctDNA) liquid biopsy assays, and PD-L1 expression scores;
• Original Digital Imaging: High-resolution chest CT, brain MRI, and PET-CT scans provided in raw digital DICOM format;
• Prior Treatment Chronology: Operative reports, radiation records, and complete systemic therapy history (exact targeted drugs, chemotherapy combinations, immunotherapies, duration, best clinical response, and progression dates);
• General Organ Function Profiles: Recent complete blood counts, hepatic and renal panels, pulmonary function tests, and cardiac assessments.

Disclaimer: Information on this page regarding Guangdong Provincial People's Hospital (GDPH) is compiled from official hospital records, academic clinical research, and public medical directories. Specific details concerning clinic schedules, participating trial protocols, and departmental rosters are subject to adjustment by the hospital. Always consult official hospital announcements or licensed medical specialists for clinical verification.

Notice: China Medical Concierge - Shanghai (CMCS) is an independent health management and medical concierge service provider, not a hospital or clinic. We do not provide direct medical diagnoses or therapeutic treatments. All medical consultations and treatments are performed independently by licensed physicians at partner hospitals.